These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23578031)

  • 1. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
    Allen A; Schenkenberger I; Trivedi R; Cole J; Hicks W; Gul N; Jacques L
    Clin Respir J; 2013 Oct; 7(4):397-406. PubMed ID: 23578031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
    Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
    Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L; Bateman ED
    Thorax; 2013 Jun; 68(6):513-20. PubMed ID: 23440247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R; Allen A; Bareille P; Hamilton M; Cheesbrough A
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
    Bateman ED; O'Byrne PM; Busse WW; Lötvall J; Bleecker ER; Andersen L; Jacques L; Frith L; Lim J; Woodcock A
    Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
    J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
    O'Byrne PM; Bleecker ER; Bateman ED; Busse WW; Woodcock A; Forth R; Toler WT; Jacques L; Lötvall J
    Eur Respir J; 2014 Mar; 43(3):773-82. PubMed ID: 24136330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
    Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
    Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
    Kempsford R; Allen A; Kelly K; Saggu P; Crim C
    Br J Clin Pharmacol; 2014 Mar; 77(3):466-79. PubMed ID: 24093504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
    Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
    Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
    Daley-Yates PT; Deans A; Mehta R; Sousa AR
    Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination.
    Oliver A; Bjermer L; Quinn D; Saggu P; Thomas P; Yarnall K; Lötvall J
    Allergy; 2013 Sep; 68(9):1136-42. PubMed ID: 23924233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
    Woodcock A; Bleecker ER; Lötvall J; O'Byrne PM; Bateman ED; Medley H; Ellsworth A; Jacques L; Busse WW
    Chest; 2013 Oct; 144(4):1222-1229. PubMed ID: 23846316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.